Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cybin Inc
(NY:
CYBN
)
0.2680
+0.0007 (+0.26%)
Official Closing Price
Updated: 8:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cybin Inc
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks ‘Tremendous’ Milestone as First Participants Receive Initial CYB003 Dose
September 20, 2022
Via
Investor Brand Network
Cybin Achieves Research and Development Milestones Ahead of Projected Timelines
September 20, 2022
From
Cybin Inc.
Via
Business Wire
Study Suggests Reported Psychedelics Microdosing Effects Are Due to User Expectancy
September 15, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marking Industry’s First-Ever Entry of Novel Psilocybin Analog into Clinical Development
September 14, 2022
Via
Investor Brand Network
Study Finds That LSD Temporarily Reduces Binge Drinking in Rodents
September 07, 2022
Via
Investor Brand Network
Study Finds Hepatitis C Drugs May Help Alleviate Symptoms of PTSD
September 13, 2022
Via
Investor Brand Network
How Psychedelic Legalization, Decriminalization and Medicalization Differ
September 12, 2022
Via
Investor Brand Network
Topics
Law Enforcement
Exposures
Legal
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) on Leading Edge of Psilocybin Research
September 08, 2022
Via
Investor Brand Network
Exposures
Censorship
Psychedelics May Make People Less Afraid of Death
September 07, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 7, 2022 – According to a new survey by Johns Hopkins Medicine researchers, people’s attitudes toward death change...
Via
FinancialNewsMedia
Topics
Supply Chain
Exposures
Supply Chain
Study Highlights Need for Postnatal Depression Screening
September 02, 2022
Via
Investor Brand Network
Study Shows Psilocybin Helps Alcoholics Reduce Drinking
September 01, 2022
Via
Investor Brand Network
Exposures
Product Safety
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Adelia Marks Final Development Milestone
August 31, 2022
Via
Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD
August 31, 2022
Via
Investor Brand Network
Topics
Death
Exposures
Death
Cybin Announces Final Adelia Milestone Achievement
August 31, 2022
From
Cybin Inc.
Via
Business Wire
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Dosing Participants in CYB003 Trial for Treatment of MDD
August 30, 2022
Via
Investor Brand Network
Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder
August 30, 2022
From
Cybin Inc.
Via
Business Wire
How Psychedelics Startups Are Improving Their Resilience
August 29, 2022
Via
Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector
August 26, 2022
Via
Investor Brand Network
Israeli Study identifies Bacterial Footprint in PTSD Sufferers
August 25, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Participate in Upcoming H.C. Wainwright Global Investment Conference
August 25, 2022
Via
Investor Brand Network
Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 25, 2022
From
Cybin Inc.
Via
Business Wire
How Meditation, Psychedelics Can Boost Healing
August 24, 2022
Via
Investor Brand Network
FT-104: Field Trip’s Latest Psychedelic Drug Candidate
August 22, 2022
Via
Investor Brand Network
Study Suggests LSD May Boost Learning, Memory by Enhancing Neural Plasticity
August 18, 2022
Via
Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Partner Receive Required Schedule I License from DEA for First-in-Human Clinical Trial
August 17, 2022
Via
Investor Brand Network
Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
August 17, 2022
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Results of Annual Meeting of Shareholders
August 16, 2022
Via
Investor Brand Network
Cybin Announces Results of Shareholders’ Meeting
August 15, 2022
From
Cybin Inc.
Via
Business Wire
Psilocybin Lawsuit Filed in Canada May Boost Global Psychedelics Reform Efforts
August 12, 2022
Via
Investor Brand Network
Topics
Lawsuit
Exposures
Financial
Legal
Brain Fingerprinting Adolescents Could Predict Future Mental-Health Issues
August 10, 2022
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.